课题基金 / 基金详情

The study of therapy for canine pituitary adenomas by 11beta-HSD inhibitor

The study of therapy for canine pituitary adenomas by 11beta-HSD inhibitor
11β-HSD抑制剂治疗犬垂体腺瘤的研究
批准号:
24780315
负责人:
TESHIMA Takahiro
金额:
$2.91万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2012
资助国家:
日本
项目状态:
已结题
起止时间:
2012-04-01 至 2014-03-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
It was revealed that the effect of 11beta-HSD inhibitor on dogs was dose-dependent in this study. From the result of our study, it was suggested that ACTH secretion from pituitary was decreased by 11beta-HSD inhibitor in healthy dogs. Moreover, apparent side effects were not observed in the long term administration period of 11beta-HSD inhibitor. We have to research the effect of 11beta-HSD inhibitor on dogs with canine pituitary ACTH adenomas.In conclusion, we expect that there is possibility that 11beta-HSD inhibitor can be therapeutic drug for canine pituitary ACTH adenoma. Furthermore, we need to proceed this study for treatment of caine pituitary ACTH adenomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Expression of 11β-hydroxysteroid dehydrogenase isoforms in canine adrenal glands treated with trilostane.
用曲洛斯坦治疗的犬肾上腺中 11β-羟基类固醇脱氢酶亚型的表达。
DOI: 10.1016/j.tvjl.2014.03.022
发表时间: 2014
期刊: Veterinary Journal
影响因子: 2.2
作者: [Teshima T, Matsumoto H, Kumagai T, Kurano M, Koyama H.]
通讯作者: Koyama H.
国内基金
海外基金
BRCC3驱动女性ACTH腺瘤发病的作用及其机制研究
MIF调控EGFR-ATK/ERK信号通路对垂体ACTH腺瘤发生发展的作用与分子机制
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2022
  • 负责人:
  • 依托单位:
基氯胺酮通过背内侧前额叶皮质PV+神经元对ACTH抑郁模型小鼠工作记忆的调控及抑郁相关工作记忆改变的机制探究
  • 批准号:
    82204356
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20万元
  • 批准年份:
    2022
  • 负责人:
    张谨
  • 依托单位:
基于不同步性发育理论探讨加味地黄饮子添加治疗对ACTH无效的婴儿痉挛症的作用机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    戎萍
  • 依托单位: